atrasentan has been researched along with docetaxel anhydrous in 13 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | atrasentan (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SS; Rumohr, JA | 1 |
| Banerjee, S; Bonfil, D; Che, M; Cher, M; Hussain, M; Saliganan, A; Sarkar, FH; Wang, Z | 1 |
| Tan, W | 1 |
| Fleshner, NE; Shahani, R; Zlotta, AR | 1 |
| Azim, HA; Mok, T | 1 |
| Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S | 1 |
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Taneja, SS | 1 |
| Ely, B; Gertz, E; Goldkorn, A; Hussain, M; Lara, PN; Mack, PC; Quinn, DI; Tangen, C; Thompson, IM; Twardowski, PW; Van Loan, MD; Vogelzang, NJ | 1 |
| Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T | 1 |
| Fong, L; Friedlander, TW | 1 |
| Armstrong, AJ; Bacon, K; Creel, P; George, DJ; Hobbs, G; Hurwitz, H; McManus, TJ; Peer, CJ; Petros, WP; Younis, IR; Yu, JJ | 1 |
| Chen, M; He, ZH; Qi, P; Song, RX; Wang, ZP; Zhang, LX | 1 |
4 review(s) available for atrasentan and docetaxel anhydrous
| Article | Year |
|---|---|
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2006 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids | 2008 |
A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
4 trial(s) available for atrasentan and docetaxel anhydrous
| Article | Year |
|---|---|
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2008 |
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids | 2013 |
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Collagen Type I; Disease-Free Survival; Docetaxel; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; ROC Curve; Taxoids; Treatment Failure | 2014 |
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2014 |
5 other study(ies) available for atrasentan and docetaxel anhydrous
| Article | Year |
|---|---|
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Docetaxel; Drug Synergism; Endothelin A Receptor Antagonists; Humans; Male; Mice; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Atrasentan; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Models, Biological; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2007 |
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2014 |
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2014 |